CLOVER HEALTH INVESTMENTS, CORP. current report, 16 April 2023

Full document

Business Context and Reporting Period

Clover Health Investments, Corp. filed a Form 8-K relating to business transformation initiatives announced in April 2023. The filing states that the Master Services Agreement with UST HealthProof was entered into on April 16, 2023, effective April 14, 2023. The report is dated April 16, 2023, references an April 17 announcement, and was signed on April 20, 2023.

Key Financial and Operating Metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity amounts.
  • The initiatives are expected to generate approximately $30 million of net annual cost savings beginning in 2024.
  • Expected total charges are approximately $7.0 million to $9.0 million, primarily future cash expenditures.
  • Charges are expected to be recorded primarily in the first and second quarters of 2023 and to consist mainly of severance, implementation, legal, and related costs.
  • The reduction in force eliminated approximately 10% of the workforce.

Material Changes Versus the Prior Comparable Period

  • Clover is transitioning certain Medicare Advantage plan-operation functions to UST HealthProof’s integrated technology platform.
  • Transferred functions include claims, enrollment, contact center, medical management, payment integrity, revenue integrity, printing, fulfillment, related configuration, and certain information-technology functions.
  • Clover also implemented corporate restructuring actions to align selling, general and administrative costs with its revenue base.

Guidance, Outlook, Risks, and Unusual Items

  • The UST HealthProof services term runs through December 31, 2028, with two optional one-year renewals by Clover, subject to earlier termination rights.
  • Payments are primarily based on a fixed monthly charge per member; discretionary enhancements and ancillary projects may be billed on a time-and-materials basis.
  • The agreement is non-exclusive, but removing services may require Clover to pay certain minimum charges.
  • Projected cost savings and future profitability, liquidity, operating results, and implementation outcomes are forward-looking and may not be achieved.
  • The filing refers investors to Clover’s Form 10-K filed March 1, 2023, and other SEC filings for additional risk factors.

Important Facts for Investors to Verify

  1. Whether the expected $30 million annual savings are realized beginning in 2024 and how they affect adjusted and GAAP operating results.
  2. The timing and final amount of the $7.0 million to $9.0 million restructuring and implementation charges.
  3. The detailed economics, minimum charges, termination provisions, and service-level obligations under the UST HealthProof agreement.
  4. The effect of outsourcing core plan operations on Medicare Advantage member service, claims processing, compliance, and operating risk.
  5. Clover’s current cash balance, cash burn, debt obligations, and liquidity position, which are not disclosed in this filing.